P-206Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers. (20th June 2018) - Bruera, G; Massacese, S; Pepe, F; Malapelle, U; Dal Mas, A; Ciacco, E; Calvisi, G; Marchetti, P; Troncone, G; Simmaco, M; Ricevuto, E